A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Vinorelbine (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms VIM
- 04 Jul 2019 As per ISRCTN: Current Controlled Trials record trial is completed.
- 29 Apr 2019 Planned number of patients changed from 200 to 157.
- 29 Apr 2019 Planned End Date changed from 1 Sep 2019 to 1 Jan 2020.